Open access · CC-BY
via OpenAlex
Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice
Randy Strong, James F. Nelson, Molly A. Bogue, Jerry R. Colca, Martin Sebastian Denzel, Vivian Diaz, Brian N. Finck, Vadim N. Gladyshev, Steve Horvath, Nisi Jiang, Tracy L. Keller, Rolf F. Kletzien, Ron Korstanje, Navasuja Kumar, Christiaan Leeuwenburgh
GeroScience · 2025 · ▲ 6 citations
Abstract
Mice bred in 2021 were tested by the Interventions Testing Program (ITP) for possible lifespan benefits of 2BAct (2BA), dichloroacetate (DCA), Epicatechin (EPI), Forskolin (FSK), Halofuginone (HAL) and Mitoglitazone (MIT). All agents were administered in the diet ad libitum beginning at 7 months of age. In male mice, EPI increased median lifespan by ~ 5%, and HAL and MIT each increased median lifespan by ~ 9%. EPI and HAL, but not MIT, increased 90% survival. In addition to adding 3 new agents to the list of interventions identified by the ITP that extend lifespan, this report continues the strong male bias in the efficacy of life-extending drugs identified so far.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s11357-025-01881-6
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Strong, R., Nelson, J.F., Bogue, M.A., Colca, J.R., Denzel, M.S., Diaz, V., Finck, B.N., Gladyshev, V.N., Horvath, S., Jiang, N., Keller, T., Kletzien, R.F., Korstanje, R., Kumar, N., Leeuwenburgh, C., Fernández, E., Gałecki, A.T., Ginsburg, B.C., Han, M.L., & Kaczorowski, C.C. (2025). Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice. <em>GeroScience</em>. https://doi.org/10.1007/s11357-025-01881-6
Vancouver
Strong R, Nelson JF, Bogue MA, Colca JR, Denzel MS, Diaz V, et al. Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice. GeroScience. 2025. doi:10.1007/s11357-025-01881-6.
BibTeX
@article{randy2025Extens,
title = {Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice},
author = {Randy Strong and James F. Nelson and Molly A. Bogue and Jerry R. Colca and Martin Sebastian Denzel and Vivian Diaz and Brian N. Finck and Vadim N. Gladyshev and Steve Horvath and Nisi Jiang and Tracy L. Keller and Rolf F. Kletzien and Ron Korstanje and Navasuja Kumar and Christiaan Leeuwenburgh and Elizabeth Fernández and Andrzej T. Gałecki and Brett C. Ginsburg and Melissa L. Han and Catherine Cook Kaczorowski and Scott F. Leiser and Marisa Lopez‐Cruzan and Ken Raj and Peter C. Reifsnyder and Nadia A Rosenthal},
journal = {GeroScience},
year = {2025},
doi = {10.1007/s11357-025-01881-6},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
GeroScience 2025
Open access · CC-BY
End-of-life pathology in UM-HET3 mice treated with 16 α‑hydroxyestradiol or late‑start canagliflozin
Nephrology Dialysis Transplantation 2009
Citation only
Rapamycin enhances lifespan: At last, an advantage for transplant recipients?
GeroScience 2026
Citation only
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice.
The Journals of Gerontology Series A 2025
Open access · OA
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program
The journals of gerontology. Series A, Biological sciences and medical sciences 2025
Citation only
Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.
Aging Cell 2007
Open access · OA